Guidelines for Pediatric Unrelated Cord Blood Transplantation-Unique Considerations

Transplant Cell Ther. 2021 Dec;27(12):968-972. doi: 10.1016/j.jtct.2021.09.013. Epub 2021 Sep 24.

Abstract

Cord blood (CB) is the stem cell source of choice for approximately 30% of pediatric patients undergoing hematopoietic cell transplantation. Cord blood is readily available and is a particularly appealing stem cell source for patients who lack appropriate HLA-matched related or unrelated donors. Pediatric cord blood transplant (CBT) recipients have low rates of disease relapse in the malignant setting and very low rates of chronic graft-versus-host disease (GVHD). In addition, CB has unique properties that make it the stem cell source of choice for some nonmalignant conditions such as metabolic disorders. This review provides evidence-based and experience-based pediatric-specific guidelines for CBT including considerations for infectious disease management, CB unit selection and infusion, conditioning regimen selection, and GVHD management. In addition, it covers unique bedside considerations for pediatric patients and CB banking. In concert with the other topic specific CB guidelines previously published in this series, it provides a comprehensive overview of the clinical management of pediatric CBT.

Keywords: Guidelines; Pediatric cord blood transplantation.

Publication types

  • Practice Guideline
  • Review

MeSH terms

  • Child
  • Cord Blood Stem Cell Transplantation*
  • Fetal Blood
  • Graft vs Host Disease*
  • Hematopoietic Stem Cell Transplantation*
  • Humans
  • Unrelated Donors